PL2503338T3 - CD73 jako biomarker do monitorowania rozwoju choroby i oceny skuteczności terapii - Google Patents

CD73 jako biomarker do monitorowania rozwoju choroby i oceny skuteczności terapii

Info

Publication number
PL2503338T3
PL2503338T3 PL12002502T PL12002502T PL2503338T3 PL 2503338 T3 PL2503338 T3 PL 2503338T3 PL 12002502 T PL12002502 T PL 12002502T PL 12002502 T PL12002502 T PL 12002502T PL 2503338 T3 PL2503338 T3 PL 2503338T3
Authority
PL
Poland
Prior art keywords
biomarker
therapies
assessing
efficacy
diseases
Prior art date
Application number
PL12002502T
Other languages
English (en)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of PL2503338T3 publication Critical patent/PL2503338T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
PL12002502T 2007-10-24 2008-10-15 CD73 jako biomarker do monitorowania rozwoju choroby i oceny skuteczności terapii PL2503338T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
EP12002502.8A EP2503338B1 (en) 2007-10-24 2008-10-15 CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
EP08842581A EP2201376B1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies

Publications (1)

Publication Number Publication Date
PL2503338T3 true PL2503338T3 (pl) 2015-06-30

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08842581T PL2201376T3 (pl) 2007-10-24 2008-10-15 Nowy biomarker do monitorowania rozwoju chorób i do oceny skuteczności leczenia
PL12002502T PL2503338T3 (pl) 2007-10-24 2008-10-15 CD73 jako biomarker do monitorowania rozwoju choroby i oceny skuteczności terapii

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08842581T PL2201376T3 (pl) 2007-10-24 2008-10-15 Nowy biomarker do monitorowania rozwoju chorób i do oceny skuteczności leczenia

Country Status (14)

Country Link
US (1) US20100209942A1 (pl)
EP (2) EP2503338B1 (pl)
JP (2) JP4982610B2 (pl)
KR (2) KR20160029869A (pl)
CA (1) CA2702635A1 (pl)
CY (2) CY1113403T1 (pl)
DK (2) DK2201376T3 (pl)
ES (2) ES2532361T3 (pl)
FI (1) FI20070795A0 (pl)
HR (2) HRP20120743T1 (pl)
PL (2) PL2201376T3 (pl)
PT (2) PT2503338E (pl)
SI (2) SI2503338T1 (pl)
WO (1) WO2009053523A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101978269A (zh) 2008-01-18 2011-02-16 哈佛大学校长及研究员协会 在体液中检测疾病或病症标志的方法
WO2012012709A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting cardiovascular diseases or conditions
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
US20130184178A1 (en) 2010-07-23 2013-07-18 President And Fellows Of Harvard College Methods of Detecting Autoimmune or Immune-Related Diseases or Conditions
WO2012012725A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting diseases or conditions using phagocytic cells
KR20130041961A (ko) 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액에서 질환 또는 상태의 특징을 검출하는 방법
CN104603289A (zh) 2012-06-15 2015-05-06 哈里·斯泰利 检测疾病或病状的方法
US20150141260A1 (en) 2012-06-15 2015-05-21 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
JP6337020B2 (ja) 2013-02-14 2018-06-06 ファロン ファーマシューティカルズ オサケ ユキチュア 急性呼吸促迫症候群（ａｒｄｓ）関連バイオマーカーを測定する方法、患者におけるａｒｄｓの進行および治療をモニターする方法
EP3385717A3 (en) 2013-03-09 2018-10-24 Harry Stylli Methods of detecting prostate cancer
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
WO2016040843A1 (en) 2014-09-11 2016-03-17 Harry Stylli Methods of detecting prostate cancer
HRP20201756T8 (hr) 2014-11-21 2021-08-20 Bristol-Myers Squibb Company Antitijela koja sadrže modificirane regije teškog lanca
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
GB201706747D0 (en) * 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2228970A1 (en) * 1995-08-18 1997-02-27 Donald W. Landry Detection of organic compounds through regulation of antibody-catalyzed reactions
EP0862652A1 (en) * 1995-10-13 1998-09-09 IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) * 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
AU2002252460A1 (en) * 2001-03-27 2002-10-08 Zymogenetics, Inc. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
CA2519465C (en) * 2003-03-28 2016-08-02 Faron Pharmaceuticals Oy Elevation of adenosine level by cytokine-induced expression of cd73
EP1664073A2 (en) * 2003-06-03 2006-06-07 The Regents of the University of California Compositions and methods for treatment of disease with acetylated disaccharides
WO2007025044A2 (en) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
EP2021350B1 (en) * 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
US20100003189A1 (en) * 2006-07-14 2010-01-07 The Regents Of The University Of California Cancer biomarkers and methods of use thereof

Also Published As

Publication number Publication date
CY1116089T1 (el) 2017-02-08
EP2503338B1 (en) 2014-12-24
HRP20120743T1 (hr) 2012-10-31
CA2702635A1 (en) 2009-04-30
EP2201376A1 (en) 2010-06-30
ES2389751T3 (es) 2012-10-31
EP2503338A3 (en) 2013-03-13
EP2201376B1 (en) 2012-08-08
KR20100059902A (ko) 2010-06-04
DK2201376T3 (da) 2012-10-15
PL2201376T3 (pl) 2013-01-31
SI2503338T1 (sl) 2015-06-30
HRP20150181T1 (hr) 2015-06-19
JP2012159514A (ja) 2012-08-23
KR20160029869A (ko) 2016-03-15
EP2503338A2 (en) 2012-09-26
CY1113403T1 (el) 2016-06-22
EP2201376A4 (en) 2011-03-23
JP5619810B2 (ja) 2014-11-05
JP4982610B2 (ja) 2012-07-25
FI20070795A0 (fi) 2007-10-24
PT2201376E (pt) 2012-08-20
DK2503338T3 (en) 2015-03-09
JP2011501176A (ja) 2011-01-06
PT2503338E (pt) 2015-03-05
ES2532361T3 (es) 2015-03-26
WO2009053523A1 (en) 2009-04-30
SI2201376T1 (sl) 2012-09-28
US20100209942A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
HRP20150181T1 (hr) Cd73 kao biomarker za praä†enje razvoja bolesti i procjenu uäśinkovitosti lijeäśenja
IL216720A0 (en) New biomarkers for assessing kidney diseases
GB0724735D0 (en) Methods and biomarkers for diagnosing and monitoring psychotic disorders
GB0701626D0 (en) Methods and biomarkers for diagnosing and monitoring psychotic disorders
IL219210A0 (en) Biomarkers and methods for measuring and monitoring inflammatory disease activity
GB0608829D0 (en) In-situ measurement of physical parameters
GB0717637D0 (en) Future cardiac event biomarkers
GB2450351B (en) Monitoring an Immunoassay
IL206631A0 (en) Biomarkers for the prediction of renal injury
EP2260107A4 (en) TESTS FOR THE DIAGNOSIS AND ASSESSMENT OF TREATMENT OPTIONS FOR MORBUS POMPE
TWI351185B (en) Methods for interference measurement and prediction
EP2222689A4 (en) THERAPEUTIC AND DIAGNOSTIC COMPOUNDS
GB0712407D0 (en) Authorised debugging
EP1973351A4 (en) MONITOR
GB0704515D0 (en) Diagnosing psychotic disorders
AU2009900444A0 (en) Agents and methods for diagnosing the presence or risk of a condition
GB0606920D0 (en) Biomarker for schizophrenic disorders
PL382585A1 (pl) Sposób realizowania transakcji handlowych
PL381454A1 (pl) Sposób diagnozowania stanu technicznego obiektów mostowych
AU2008902580A0 (en) Agents and methods for diagnosing the presence or risk of a condition
GB0720545D0 (en) Diagnosing physchotic disorders
GB0622351D0 (en) Non-invasive monitoring
PL381670A1 (pl) Sposób monitorowania elementów konstrukcji
GB0811751D0 (en) Portable device for measuring the physical symptoms of disease
AU2009902698A0 (en) Agents and methods for diagnosing a condition